Aeterna Zentaris Inc. (AEZ) - Financial and Strategic SWOT Analysis Review

Date: July 5, 2016
Pages: 52
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A923627EAE5EN
Leaflet:

Download PDF Leaflet

Aeterna Zentaris Inc. (AEZ) - Financial and Strategic SWOT Analysis Review
Aeterna Zentaris Inc. (AEZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Aeterna Zentaris Inc. (Aeterna Zentaris) is a specialty biopharmaceutical company which develops and commercializes therapies for the treatment of cancer, endocrine disorders and infectious diseases. The pipeline products of the company are aimed at the treatment of various kinds of cancers including colorectal (CRC), multiple myeloma (MM), endometrial, ovarian and prostate. The company submitted New Drug Application to the FDA for its lead product, Macrilen (macimorelin) (formery AEZS-130), for the evaluation of adult growth hormone deficiency (AGHD). Some of the other pipeline products of the company include macimorelin for the treatment of cancer induced cashexia; Zoptarelin doxorubicin AEZS-120, and LHRH-Disorazol Z. Aeterna Zentaris is headquartered in Quebec, Canada.

Aeterna Zentaris Inc. Key Recent Developments

May 23, 2016: Aeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair of the Board
May 09, 2016: Aeterna Zentaris Reports First Quarter 2016 Financial and Operating Results
Mar 29, 2016: Aeterna Zentaris Reports Fourth Quarter and Full-Year 2015 Financial and Operating Results
Feb 18, 2016: Aeterna Zentaris Appoints Geneviève Lemaire as Vice President, Finance and Chief Accounting Officer
Jan 29, 2016: Aeterna Zentaris Announces Appointments to Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Aeterna Zentaris Inc. - Key Facts
Aeterna Zentaris Inc. - Key Employees
Aeterna Zentaris Inc. - Key Employee Biographies
Aeterna Zentaris Inc. - Major Products and Services
Aeterna Zentaris Inc. - Pharmaceutical Pipeline Products Data
Aeterna Zentaris Inc., Pipeline Products by Therapy Area
Aeterna Zentaris Inc., Pipeline Products by Development Phase
Aeterna Zentaris Inc. - History
Aeterna Zentaris Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Aeterna Zentaris Inc. - Business Description
Aeterna Zentaris Inc. - Corporate Strategy
Aeterna Zentaris Inc. - SWOT Analysis
SWOT Analysis - Overview
Aeterna Zentaris Inc. - Strengths
Strength - Focused Research and Development
Strength - Perifosine - Orphan and Fast Track Designations
Aeterna Zentaris Inc. - Weaknesses
Weakness - History of Operating Losses
Weakness - Complete Response Letter
Aeterna Zentaris Inc. - Opportunities
Opportunity - Strong Product Pipeline
Opportunity - Changing Demographics
Opportunity - Market Potential - Oncology
Opportunity - Strategic Partnerships
Aeterna Zentaris Inc. - Threats
Threat - Increasing Competition
Threat - Dependence on Third Parties
Threat - Stringent Government Regulations
Aeterna Zentaris Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Aeterna Zentaris Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Aeterna Zentaris Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Aeterna Zentaris Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 23, 2016: Aeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair of the Board
May 09, 2016: Aeterna Zentaris Reports First Quarter 2016 Financial and Operating Results
Mar 29, 2016: Aeterna Zentaris Reports Fourth Quarter and Full-Year 2015 Financial and Operating Results
Feb 18, 2016: Aeterna Zentaris Appoints Geneviève Lemaire as Vice President, Finance and Chief Accounting Officer
Jan 29, 2016: Aeterna Zentaris Announces Appointments to Board of Directors
Jan 13, 2016: Aeterna Zentaris affirms focus on targeted oncology during 34th Annual J.P. Morgan Healthcare Conference
Nov 25, 2015: Aeterna Zentaris Affirms Fundamental Strength of Business
Nov 18, 2015: Aeterna Zentaris Announces Details and Implementation of Share Consolidation to Regain NASDAQ Compliance
Nov 05, 2015: Aeterna Zentaris Reports Third Quarter Financial and Operating Results
Oct 12, 2015: Aeterna Zentaris Announces Restructuring of Finance & Accounting Operations and Closure of Quebec City Office

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Aeterna Zentaris Inc., Key Facts
Aeterna Zentaris Inc., Key Employees
Aeterna Zentaris Inc., Key Employee Biographies
Aeterna Zentaris Inc., Major Products and Services
Aeterna Zentaris Inc., Number of Pipeline Products by Therapy Area
Aeterna Zentaris Inc., Number of Pipeline Products by Development Stage
Aeterna Zentaris Inc., Pipeline Products By Therapy Area and Development Phase
Aeterna Zentaris Inc., History
Aeterna Zentaris Inc., Subsidiaries
Aeterna Zentaris Inc., Key Competitors
Aeterna Zentaris Inc., Ratios based on current share price
Aeterna Zentaris Inc., Annual Ratios
Aeterna Zentaris Inc., Interim Ratios
Aeterna Zentaris Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Aeterna Zentaris Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Aeterna Zentaris Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Aeterna Zentaris Inc., Pipeline Products by Therapy Area
Aeterna Zentaris Inc., Pipeline Products by Development Phase
Aeterna Zentaris Inc., Performance Chart (2011 - 2015)
Aeterna Zentaris Inc., Ratio Charts
Aeterna Zentaris Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Aeterna Zentaris Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

Aeterna Zentaris Inc. (AEZ) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: